TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
about
PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.Arsenic attenuates Heparin-binding EGF-like growth factor/EGFR signalling that promotes matrix-metalloprotease-9-dependent astrocyte damage in the developing rat brain.Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2.Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy
P2860
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TC-N19, a novel dual inhibitor ...... -small-cell lung cancer cells.
@en
TC-N19, a novel dual inhibitor ...... -small-cell lung cancer cells.
@nl
type
label
TC-N19, a novel dual inhibitor ...... -small-cell lung cancer cells.
@en
TC-N19, a novel dual inhibitor ...... -small-cell lung cancer cells.
@nl
prefLabel
TC-N19, a novel dual inhibitor ...... -small-cell lung cancer cells.
@en
TC-N19, a novel dual inhibitor ...... -small-cell lung cancer cells.
@nl
P2093
P2860
P356
P1476
TC-N19, a novel dual inhibitor ...... n-small-cell lung cancer cells
@en
P2093
P2860
P356
10.1038/CDDIS.2016.192
P577
2016-06-30T00:00:00Z